Note 1 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended
	Apr. 19, 2023	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Number of Tumor Samples		150,000
Number of Operating Segments		3
Cash and Cash Equivalents, at Carrying Value		$ 18,597,119		$ 22,071,523
Long-term Debt, Total		0
Accounts Receivable, Allowance for Credit Loss, Current		0
Accounts Receivable, after Allowance for Credit Loss		282,763		331,196
Contract with Customer, Liability		639,238		$ 602,073
Research and Development Expense		38,805	$ 68,219
Income Tax Expense (Benefit), Total		0
Unrecognized Tax Benefits, Ending Balance		0
Cash, Uninsured Amount		$ 57,750
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20